8-K: Aprea Therapeutics Secures $34 Million in Private Placement, Advances Clinical Programs

Aprea Therapeutics has announced a private placement financing of up to $34 million to support its clinical development programs.

Summary

• Aprea Therapeutics has entered into a securities purchase agreement for a private placement expected to raise up to $34 million.
• The financing includes $16 million in upfront gross proceeds and up to an additional $18 million from potential warrant exercises.
• The private placement is led by Sphera Healthcare with participation from other healthcare-focused institutional investors.
• The funds will support the Phase 1 ACESOT-1051 clinical trial for APR-1051, a WEE1 inhibitor, and the ongoing Phase 1/2a trial for ATRN-119, an ATR inhibitor.
• The company will issue 2,194,788 shares of common stock (or pre-funded warrants) and accompanying warrants.
• Tranche A warrants are exercisable at $7.29 per share, and Tranche B warrants at $9.1125 per share.
• The closing of the private placement is expected on or about March 13, 2024.
• Aprea also announced that the FDA has cleared the Investigational New Drug Application for APR-1051.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a successful capital raise and a key regulatory approval. However, the potential dilution from the share issuance and the contingent nature of the warrant proceeds temper the overall sentiment.

Positives

• The private placement provides significant funding to advance clinical programs.
• The financing is led by high-quality healthcare institutions.
• The FDA clearance of the IND for APR-1051 is a positive regulatory milestone.
• The company expects to be funded into 2026 with the proceeds.
• The company has terminated its at-the-market offering agreement with H.C. Wainwright & Co., LLC.

Negatives

• The private placement involves the issuance of new shares, which may dilute existing shareholders.
• The potential for additional funding is contingent on warrant exercises, which may not occur.
• The warrants have specific exercise conditions tied to future clinical trial announcements and stock price performance.

Risks

• The company's ability to achieve the full $34 million in funding depends on warrant exercises.
• The exercise of warrants is contingent on the company's stock price reaching certain levels.
• The company's clinical trials may not be successful.
• The company may face challenges in obtaining regulatory approvals for its product candidates.
• The company may not be able to maintain its listing on the Nasdaq.

Future Outlook

The company intends to use the net proceeds from the private placement for general corporate purposes and to fund clinical development of APR-1051, with the aggregate net proceeds (assuming the cash exercise of all accompanying warrants) expected to be sufficient to fund the Company into 2026.

Management Comments

• This meaningful financing led by high quality healthcare institutions will support Aprea in our goal to be a leader in the field of Synthetic Lethality (SL) and DNA Damage and Response (DDR), said Dr. Oren Gilad, President and CEO of Aprea.
• It will provide the capital to fund our Phase 1 ACESOT-1051, clinical trial evaluating a highly potent, oral WEE1 inhibitor for Cyclin E over-expressing cancers including breast and ovarian cancers as well as continuation of patient enrollment in the dose expansion portion of the Phase 1/2a clinical trial (AR-276-01) evaluating ATR inhibitor, ATRN-119, in patients with advanced solid tumors having mutations in defined DDR-related genes.
• The FDA's clearance of our IND is a critical step in the APR-1051 development program. We look forward to evaluating therapeutic activity in patients, focusing on Cyclin E overexpressing cancers, including ovarian and breast cancers.

Industry Context

This announcement reflects a continued interest in precision oncology and synthetic lethality approaches, with investors focusing on companies developing targeted therapies for specific cancer subtypes. The financing also highlights the importance of clinical trial progress and regulatory milestones in attracting investment in the biotech sector.

Comparison to Industry Standards

• The private placement structure, including the use of warrants, is a common method for raising capital in the biotech industry, particularly for clinical-stage companies.
• The size of the financing, up to $34 million, is typical for companies at Aprea's stage of development.
• The focus on WEE1 and ATR inhibitors aligns with current trends in cancer drug development, targeting key DNA damage response pathways.
• The company's focus on Cyclin E overexpressing cancers is a specific niche within the broader oncology space, which may provide a competitive advantage.
• The company's claim of APR-1051 being potentially best-in-class is a common marketing strategy in the biotech industry, but will need to be validated by clinical data.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company's employees will benefit from the increased financial stability and the advancement of clinical programs.
• Patients may benefit from the development of new cancer therapies.
• Investors will have the opportunity to participate in the company's growth potential.

Next Steps

• The company expects to close the private placement on or about March 13, 2024.
• Aprea intends to use the upfront net proceeds from the private placement for general corporate purposes and to fund clinical development of APR-1051.
• The company plans to initiate the Phase 1 ACESOT-1051 dose escalation trial for APR-1051.
• The company expects to provide an update from the ACESOT-1051 clinical trial in Q4 2024.

Key Dates

Keywords

private placement, financing, clinical trials, WEE1 inhibitor, ATR inhibitor, APR-1051, ATRN-119, FDA, IND, oncology, synthetic lethality, DNA damage response